Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

Exclusion Criteria

• •The participant has any clinically significant, uncontrolled medical condition (treated or untreated) that would interfere with the study schedule or procedures, interpretation of efficacy results, or compromise the patient's safety.
• •The participant has another confounding underlying lung disorder
• •The participant has a known hypereosinophilic syndrome.
• •The participant has a diagnosis of malignancy within 5 years of the screening visit, except for treated and cured non-melanoma skin cancers.
• •The participant is a pregnant or lactating woman, or intends to become pregnant during the study. Any woman becoming pregnant during the study will be withdrawn from the study.
• •The participant is a current smoker or has a smoking history.
• •The participated in a clinical trial within 30 days or 5 half-lives of the investigational drug before screening, whichever is longer.
• •The participant was previously exposed to reslizumab.
• •The participant has a history of an immunodeficiency disorder including human immunodeficiency virus (HIV).
• •The participant has current or suspected drug and alcohol abuse.
• •The participant has an active helminthic parasitic infection or was treated for one within 6 months of screening.
• •The participant has a history of allergic reaction or hypersensitivity to any component of the study drug.
• •* Additional criteria may apply, please contact the investigator for more information